Overview

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2022-10-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.

Phase:

Phase 1

Details

Lead Sponsor:

Aragon Pharmaceuticals, Inc.

Treatments:

Abiraterone Acetate
Prednisone